Auris

Survey Finds Nearly 1 in 2 Americans are Concerned About Contracting an Infectious Disease from a Hospital

Retrieved on: 
Thursday, November 9, 2023
Woman, Hispanic, Ageing, Infection, Auris, Black people, Fear, YouGov, Disinfectant, Houston, White, Fungal infection, Risk, Hospital, Centers for Disease Control and Prevention, Patient, Health insurance, Nursing, Birth control, White people

The findings, which arrive on the heels of the pandemic and amidst an escalating infectious disease crisis, reflect consumer sentiment and concerns when seeking medical care.

Key Points: 
  • The findings, which arrive on the heels of the pandemic and amidst an escalating infectious disease crisis, reflect consumer sentiment and concerns when seeking medical care.
  • Sixty-eight percent (68%) of Americans expressed concern about the cleanliness of surfaces in a hospital, with 31% noting they are very concerned.
  • Findings also show that younger Americans and women generally harbor greater concerns about hospital infections and cleanliness than older Americans or men.
  • Fifty-one percent (51%) of women said they may contract an infectious disease from a hospital room, compared to only 41% for men.

Highlight from Kinnos Recognized as One of TIME’s Best Inventions of 2023

Retrieved on: 
Tuesday, October 24, 2023
Auris, TIME, Invention, Fast, Infection, Houston, Design, Fungal infection, Hospital, Ebola, Patient, Pharmaceutical industry, Vaccine

BROOKLYN, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kinnos today announced that Highlight®, its novel technology for colorizing disinfectant wipes, earned a special mention in the TIME Best Inventions of 2023 list.

Key Points: 
  • BROOKLYN, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kinnos today announced that Highlight®, its novel technology for colorizing disinfectant wipes, earned a special mention in the TIME Best Inventions of 2023 list.
  • New threats like Candida auris continue to emerge just as multiple studies show that less than 50% of hospital surfaces are properly cleaned.
  • The result is a list of inventions that are changing how we live, work, play, and think about what’s possible.
  • Highlight from Kinnos was also recently recognized in the Fast Company 2023 Innovation by Design awards.

SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

Retrieved on: 
Tuesday, October 24, 2023
Yeast, TIMM, European Confederation, IV, Antimalarial medication, Auris, Candida albicans, Biotechnology, Congress, Professor, ECMM, Mouse, Candida auris, University of Graz, University, Medical Mycology, Fungal infection, Patient, Associate, Mycology, Pharmaceutical industry

JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens.

Key Points: 
  • JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens.
  • “We are excited to see the progress in the development of this novel compound from the fungerp family,” said Dr. Martin Hoenigl, FECMM, Associate Professor of Translational Mycology at University of Graz, Austria and president of the European Confederation of Medical Mycology (ECMM).
  • Results illustrated the potent and broad-spectrum in vitro activity of SCY-247, including against a large array of yeasts, molds and dimorphic fungi.
  • Results also demonstrated SCY-247’s extensive tissue distribution in mice, including brain penetration.

T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement

Retrieved on: 
Monday, October 23, 2023
FDA, Partnership, Therapy, Term loan, CRG, Auris

LEXINGTON, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC (“CRG”).

Key Points: 
  • LEXINGTON, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC (“CRG”).
  • No other material amendments were made to the Term Loan Agreement.
  • “We continue to be excited by T2 Biosystems’ direct-from-blood diagnostic technology and its ability to rapidly detect sepsis-causing pathogens and antibiotic resistance genes,” said Luke Düster, partner at CRG.
  • “We value our partnership with CRG and we appreciate the continued support of our business strategy.”

New UVDI-GO™ UV LED Surface Sanitizer Inactivates High-Risk Microorganisms in 20 Seconds or Less

Retrieved on: 
Wednesday, October 18, 2023
Medical Supplies, Health, Hospitals, Health Technology, Other Health, General Health, Tablet, Innovative Satellite Technology Demonstration Program, Healthcare Facilities Accreditation Program, Innovation, Disinfectant, Auris, Multimedia, Sewage treatment

The UVDI-GO™ has demonstrated 99.99% and greater inactivation of common healthcare microorganisms, including C. difficile spores and Candida auris, from surfaces in 20 seconds or less at 4” (10.2 cm) distance in independent laboratory testing.

Key Points: 
  • The UVDI-GO™ has demonstrated 99.99% and greater inactivation of common healthcare microorganisms, including C. difficile spores and Candida auris, from surfaces in 20 seconds or less at 4” (10.2 cm) distance in independent laboratory testing.
  • Its fast efficacy, safe use on surfaces and portability enable rapid, on-the-go surface disinfection by trained healthcare professionals.
  • View the full release here: https://www.businesswire.com/news/home/20231017568803/en/
    The new UVDI-GO UV LED Surface Sanitizer inactivates C. difficile spores in only 20 seconds from 4" (10.2 cm) away (Photo: Business Wire)
    The UVDI-GO features independently proven 99.99% and greater inactivation of hard-to-kill microorganisms in 20 seconds or less at 4” (10.2 cm) distance:
    The UVDI-GO is safe for use on common healthcare surfaces.
  • A rechargeable lithium-ion battery provides two hours of run time per charge for efficient, point-of-use surface disinfection.

T2 Biosystems Announces Preliminary Third Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Thursday, October 12, 2023
ATM, COVID-19, Auris, Sepsis, Total, FDA, CRG, Instrument, International, Therapy, Video game, Medical device, Pharmaceutical industry, Acinetobacter baumannii

LEXINGTON, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial results for the third quarter ended September 30, 2023 and business updates.

Key Points: 
  • LEXINGTON, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial results for the third quarter ended September 30, 2023 and business updates.
  • Executed contracts for 5 T2Dx Instruments during the third quarter, including 2 in the U.S. and 3 internationally.
  • The Company’s third quarter 2023 financial results are preliminary and are subject to the completion of the review of the Company’s third quarter 2023 financial statements.
  • Complete third quarter 2023 financial results will be announced in November.

Morgan Stanley Expands Global Inclusive Ventures Lab with Largest Single Cohort of 23 Companies

Retrieved on: 
Tuesday, September 12, 2023
Professional Services, Business, Small Business, Start-Up, Finance, Banking, Morgan Stanley, Endometriosis, Stanley, Corporate social responsibility, Lab, Curriculum, ML, Woman, Auris, Tenant, Black, MS, Restaurant, Water, CO2, Diagnosis, NYSE, Cryptocurrency, Medical device

Morgan Stanley (NYSE: MS) today announced the 2023 global cohort of the Inclusive Ventures Lab , with 23 companies selected across North America and Europe, the Middle East and Africa (EMEA), double the size of previous cohorts.

Key Points: 
  • Morgan Stanley (NYSE: MS) today announced the 2023 global cohort of the Inclusive Ventures Lab , with 23 companies selected across North America and Europe, the Middle East and Africa (EMEA), double the size of previous cohorts.
  • Companies in the cohort receive a $250,000 investment (£250,000 in EMEA) from Morgan Stanley, as well as a variety of mentorship opportunities and business-growth resources from Morgan Stanley’s ecosystem of internal and external partners.
  • “We are proud to welcome the Lab’s largest cohort yet, marking our continued efforts to create a more equitable investment landscape for overlooked entrepreneurs worldwide,” said Selma Bueno, Global Head of the Morgan Stanley Inclusive Ventures Group.
  • The Inclusive Ventures Lab has won multiple Gold Anthem Awards, including Most Impactful Corporate Initiative in 2022 and Corporate Social Responsibility in 2023.

SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 14, 2023
Workforce, Mucorales, GSK, Hansoh Pharmaceutical, IV, SG, Ibrexafungerp, General Administration of Sport of China, Biotechnology, NDA, NIH, Candidiasis, Global health, Tablet, End-user license agreement, Silicon, Congress, Antimalarial medication, ECCMID, VVC, Investment, European, License, Research, IND, NMPA, Infection, Auris, FURI, Pharmaceutical industry, Cryptocurrency

JERSEY CITY, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • JERSEY CITY, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the second quarter ended June 30, 2023.
  • On June 21, 2023, SCYNEXIS announced the achievement of a $25 million performance-based development milestone under its exclusive license agreement with GSK for ibrexafungerp.
  • Selling, general & administrative (SG&A) expense for Q2 2023 decreased to $7.5 million from $15.8 million for Q2 2022.
  • Total other income was $5.7 million for Q2 2023, versus total other income of $8.4 million for Q2 2022.

COPPER-INFUSED SOLID SURFACE KILLS DRUG-RESISTANT FUNGUS PLAGUING NURSING HOMES

Retrieved on: 
Monday, August 14, 2023
Infection, Life, Bloodstream infections, Health, Candida auris, Nursing, Work, Copper, Patient, Risk, Mortality, Bacteria, Hand, Gram-positive bacteria, Spore, Caregiver, Auris, Vaccine, Pharmaceutical industry

NORFOLK, Va., Aug. 14, 2023 /PRNewswire/ -- Over the past decade, an emerging threat has affected America's 1.3 million nursing home residents: Candida auris, a fungus that causes dangerous, often fatal, bloodstream infections. From the first case in 2013, this fungus is now the cause of over 2,300 cases, with a mortality rate of 30-60%. i This high death rate is due in part its resistance to all first-line antifungal treatments as well as many treatments of last resort. Candida auris is also extremely difficult to eradicate from surfaces, where it can live (and reproduce) for many weeks, all the while releasing spores.ii Even after cleaning, surfaces become recontaminated after only 2 hours, long before the next cleaning takes place. iii

Key Points: 
  • From the first case in 2013, this fungus is now the cause of over 2,300 cases, with a mortality rate of 30-60%.
  • iii
    While nursing homes (and other healthcare facilities) are working hard and doing their best to keep the fungus at bay with traditional cleaning methods, those efforts are not making enough of a difference.
  • This fungus is hardy, resistant, and requires only small exposures to lead to a life-threatening infection.
  • Testing results show EOScu kills 99.992% of Candida auris colonies and spores in under 2 hours, a 5.25 Log reduction.

BioGX Candida Auris PCR Assay Global Adoption Accelerates

Retrieved on: 
Monday, July 24, 2023
Medical laboratory, Engineer Research and Development Center, PixL, Doctor of Philosophy, Candida auris, Somatosensory system, Hospital, Laboratory, Pathology, Cedars-Sinai Medical Center, Research, PCR, Auris, BD, Medical device

BIRMINGHAM, AL, July 25, 2023 - (ACN Newswire) - BioGX, a global provider of easy molecular diagnostic solutions, announced accelerated adoption of their high performance Sample-Ready(TM) PCR assay* for detection of Candida auris, a rapidly spreading, hard to treat fungus with a growing presence in hospitals and long-term care facilities.

Key Points: 
  • BIRMINGHAM, AL, July 25, 2023 - (ACN Newswire) - BioGX, a global provider of easy molecular diagnostic solutions, announced accelerated adoption of their high performance Sample-Ready(TM) PCR assay* for detection of Candida auris, a rapidly spreading, hard to treat fungus with a growing presence in hospitals and long-term care facilities.
  • A complete PCR mix is provided in a single lyophilized tube format to be validated by laboratories on a variety of real-time PCR instruments including the BD MAX, ThermoFisher QuantStudio, BioRAD CFX Touch and the new BioGX pixl(TM) platform.
  • "Our platform agnostic Candida auris PCR assay has been successfully validated and implemented by numerous public health laboratories and hospitals," said Shahin Iqbal, PhD, BioGX President & COO."
  • Dr. Margie Morgan, Director, Clinical Microbiology Pathology and Laboratory Medicine at Cedars Sinai Hospital in California said "the BioGX Candida auris PCR assay provides a rapid and sensitive method to perform surveillance testing for our patient population.